{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:57:02Z","timestamp":1774360622952,"version":"3.50.1"},"reference-count":68,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Experimental Therapeutics Center of Memorial Sloan Kettering"},{"name":"Commonwealth Foundation for Cancer Research"},{"name":"Technology Development Investment Fund of Memorial Sloan Kettering"},{"name":"NIH\/NCI Cancer Center","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>EGFR signaling, which requires ligand shedding by ADAM proteases, drives the progression of a variety of cancers, including breast, ovarian and lung. We previously reported the generation and characterization of a fully human, affinity-matured anti-ADAM17 monoclonal antibody, D8P1C1, which inhibits both the proliferation of an array of cancer cell lines in vitro as well as breast cancer growth in a mouse xenograft model. Here, we show that the mAb inhibits the shedding of EGFR ligands and EGFR phosphorylation in cancer cell lines, thus explaining its anti-tumor effects. In a xenograft model with a high-grade serous ovarian cancer (HGSOC) cell line, D8P1C1 showed only modest therapeutic effect, without any discernible toxicity. These results suggest that ovarian cancers are less susceptible than breast cancers to therapeutic targeting of ADAM17- or EGFR-dependent signaling. Radioimmuno PET imaging with 89Zr-DFO-D8P1C1 confirmed tumoral accumulation of the mAb in high-grade and non-high-grade serous ovarian tumor xenografts. Furthermore, we report the generation and preliminary characterization of a bispecific T cell engager derivative of D8P1C1 with improved anti-tumor efficacy in vitro.<\/jats:p>","DOI":"10.3390\/ijms27072936","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:58:59Z","timestamp":1774357139000},"page":"2936","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of the D8P1C1 Anti-ADAM17 Inhibitory Monoclonal Antibody and Generation of Its Bispecific T-Cell Engager Derivative"],"prefix":"10.3390","volume":"27","author":[{"given":"Nayanendu","family":"Saha","sequence":"first","affiliation":[{"name":"Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Gyu","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"de Stanchina","sequence":"additional","affiliation":[{"name":"Antitumor Assessment Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachelle P.","family":"Mendoza","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8201-622X","authenticated-orcid":false,"given":"Darren R.","family":"Veach","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8774-5061","authenticated-orcid":false,"given":"Dimitar B.","family":"Nikolov","sequence":"additional","affiliation":[{"name":"Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","article-title":"Epidermal growth factor receptor (EGFR) signaling in cancer","volume":"366","author":"Normano","year":"2006","journal-title":"Gene"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"8325","DOI":"10.1074\/jbc.M608826200","article-title":"Post-transcriptional Up-regulation of ADAM17 upon Epidermal Growth Factor Receptor Activation and in Breast Tumors","volume":"282","author":"Esselens","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_3","first-page":"e155296","article-title":"ADAM17-mediated EGFR ligand shedding directs macrophage-promoted cancer cell invasion","volume":"7","author":"Gnosa","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1158\/0008-5472.CAN-09-3763","article-title":"ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer","volume":"70","author":"Baumgart","year":"2010","journal-title":"Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrc2459","article-title":"The ADAMS: Signalling scissors in the tumour microenvironment","volume":"8","author":"Murphy","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/annonc\/mds279","article-title":"ADAM-17: A novel therapeutic target for triple negative breast cancer","volume":"24","author":"McGowan","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Rogmans, C., Kuhlmann, J.D., Hugendieck, G., Link, T., Arnold, N., Weimer, J.P., Fl\u00f6rkemeier, I., Rambow, A.C., Lieb, W., and Maass, N. (2021). ADAM17\u2014A Potential Blood-Based Biomarker for Detection of Early-Stage Ovarian Cancer. Cancers, 13.","DOI":"10.3390\/cancers13215563"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.2174\/138161209788682398","article-title":"ADAM17 as a therapeutic target in multiple diseases","volume":"15","author":"Arribas","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1101\/gad.1039703","article-title":"The ADAMs family of metalloproteases: Multidomain proteins with multiple functions","volume":"17","author":"Seals","year":"2003","journal-title":"Genes. Dev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2005.08.014","article-title":"Adam meets Eph: An ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans","volume":"123","author":"Janes","year":"2005","journal-title":"Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.canlet.2019.10.003","article-title":"ADAM proteases: Emerging role and targeting of the non-catalytic domains","volume":"467","author":"Saha","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1084\/jem.20151095","article-title":"An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growth","volume":"213","author":"Atapattu","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"114494","DOI":"10.1016\/j.biopha.2023.114494","article-title":"Fully human monoclonal antibody targeting activated ADAM10 on colorectal cancer cells","volume":"161","author":"Saha","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nrd2092","article-title":"Targeting proteases: Successes, failures, and future prospects","volume":"5","author":"Turk","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101265","DOI":"10.1016\/j.tranon.2021.101265","article-title":"Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells","volume":"15","author":"Saha","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: Pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1002\/cam4.2560","article-title":"Ovarian cancer: Current status and strategies for improving therapeutic outcomes","volume":"8","author":"Chandra","year":"2019","journal-title":"Cancer Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1158\/1535-7163.MCT-14-1040","article-title":"Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways","volume":"14","author":"Sabol","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"143212","DOI":"10.1016\/j.ijbiomac.2025.143212","article-title":"Transforming growth factor alpha: Key insights into physiological role, cancer therapeutics, and biomarker potential","volume":"310","author":"Gaba","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/jcb.240450407","article-title":"EGF and TGF-\u03b1 in wound healing and repair","volume":"45","author":"Schultz","year":"1991","journal-title":"J. Cell Biochem."},{"key":"ref_22","first-page":"2587","article-title":"TACE-dependent TGF-alpha shedding drives triple-negative breast cancer cell invasion","volume":"133","author":"Giricz","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_23","first-page":"5475","article-title":"Epidermal Growth Factor Promotes MDA-MB-231 Breast Cancer Cell Migration through a Phosphatidylinositol 3\u2032-Kinase and Phospholipase C-dependent Mechanism","volume":"59","author":"Price","year":"1999","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/0925-4439(92)90061-Q","article-title":"Growth regulation of ovarian cancer cells by epidermal growth factor and transforming growth factors \u03b1 and \u03b21","volume":"1180","author":"Zhou","year":"1992","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ebott, J., McAdams, J., Kim, C., Jansen, M., Woodman, P.D., La Cruz, J., Schrol, C., and Ribeiro, N.J. (2024). Enhanced amphiregulin exposure promotes modulation of the high grade serous ovarian cancer tumor immune microenvironment. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1375421"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Narasimhan, H., Ferraro, F., Bleilevens, A., Weiskirchen, R., Stickeler, E., and Maurer, J. (2022). Tumor Necrosis Factor-\u03b1 (TNF\u03b1) Stimulate Triple-Negative Breast Cancer Stem Cells to Promote Intratumoral Invasion and Neovasculogenesis in the Liver of a Xenograft Model. Biol., 11.","DOI":"10.3390\/biology11101481"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41420-023-01524-9","article-title":"The role of CXCL family members in different diseases","volume":"9","author":"Zhao","year":"2023","journal-title":"Cell Death Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"31018","DOI":"10.1074\/jbc.M109.006775","article-title":"Metalloprotease ADAM10 Is Required for Notch1 Site 2 Cleavage","volume":"284","author":"Verlaan","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2288213","DOI":"10.1080\/09537104.2023.2288213","article-title":"Tissue inhibitors of metalloproteinases (TIMPs) modulate platelet ADAM10 activity","volume":"34","author":"Lee","year":"2023","journal-title":"Platelets"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.lfs.2013.12.028","article-title":"A disintegrin and metalloproteinase 17 (ADAM17) mediates epidermal growth factor receptor transactivation by angiotensin II on hepatic stellate cells","volume":"97","author":"Oikawa","year":"2014","journal-title":"Life Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1017\/S0007114511007057","article-title":"Enhanced anti-inflammatory effect of resveratrol and EPA in treated endotoxin-activated RAW 264.7 macrophages","volume":"108","author":"Calay","year":"2012","journal-title":"Br. J. Nutr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41416-019-0654-8","article-title":"Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers","volume":"122","author":"Tuna","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1158\/0008-5472.CAN-06-4512","article-title":"Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models","volume":"67","author":"Chen","year":"2007","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ygyno.2013.07.112","article-title":"The anti-chemoresistant effect and mechanism of MUC1 aptamer-miR-29b chimera in ovarian cancer","volume":"131","author":"Dai","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Yoon, J.K., Park, B.N., Ryu, E.K., An, Y.S., and Lee, S.J. (2020). Current Perspectives on 89Zr-PET Imaging. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124309"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"117605","DOI":"10.1016\/j.biopha.2024.117605","article-title":"Fully human monoclonal antibody targeting the cysteine-rich substrate-interacting region of ADAM17 on cancer cells","volume":"180","author":"Saha","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1158\/1078-0432.CCR-11-1270","article-title":"EpCAM\/CD3-bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells","volume":"18","author":"Cioffi","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"57964","DOI":"10.18632\/oncotarget.19865","article-title":"CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1+ tumor cells, and extends the survival of tumor-bearing humanized mice","volume":"8","author":"Horn","year":"2017","journal-title":"Oncotarget"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7675","DOI":"10.1073\/pnas.0402295101","article-title":"Crystal structure of the human T cell receptor CD3\u03b5\u03b3 heterodimer complexed to the therapeutic mAb OKT3","volume":"101","author":"Dunstone","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.molimm.2015.02.008","article-title":"Subcellular localization and activation of ADAM proteases in the context of FasL shedding in T lymphocytes","volume":"65","author":"Ebsen","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/emmm.201302899","article-title":"TNF\u03b1 cleavage beyond TACE\/ADAM17: Matrix metalloproteinase 13 is a potential therapeutic target in sepsis and colitis","volume":"5","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Link, M.A., L\u00fccke, K., Schmid, J., Schumacher, V., Eden, T., Rose-John, S., and Mittr\u00fccker, H.W. (2017). The role of ADAM17 in the T-cell response against bacterial pathogens. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0184320"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.1046\/j.1432-1327.2000.01606.x","article-title":"Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cytotoxicity","volume":"267","author":"Wilson","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"102625","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing","volume":"52","author":"Engelbertsa","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1200\/JCO.2015.64.9970","article-title":"Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma","volume":"34","author":"Smits","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1073\/pnas.1000976107","article-title":"T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells","volume":"107","author":"Lutterbuese","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","first-page":"166","article-title":"Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer","volume":"30","author":"Ramalingam","year":"2016","journal-title":"Oncology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41698-018-0063-0","article-title":"Tumor evolution and chemoresistance in ovarian cancer","volume":"2","author":"Kim","year":"2018","journal-title":"NPJ Precis. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.clon.2020.03.005","article-title":"Targeting DNA repair in ovarian cancer treatment resistance","volume":"32","author":"Bowden","year":"2020","journal-title":"Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e12338","DOI":"10.1002\/jev2.12338","article-title":"Chemotherapy-induced release of ADAM17 bearing EV as a potential resistance mechanism in ovarian cancer","volume":"12","author":"Hugendieck","year":"2023","journal-title":"J. Extracell. Vesicles"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Hedemann, N., Herz, A., Schiepanski, J.H., Dittrich, J., Sebens, S., Dempfle, A., Feuerborn, J., Rogmans, C., Tribian, N., and Fl\u00f6rkemeier, I. (2021). ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids. Cancers, 13.","DOI":"10.3390\/cancers13092039"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1158\/0008-5472.CAN-15-1050","article-title":"Understanding unique attributes of MUC16 (CA125): Potential implications in targeted therapy","volume":"75","author":"Das","year":"2015","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"928","DOI":"10.4161\/mabs.28744","article-title":"Characterization and screening of IgG binding to the neonatal Fc receptor","volume":"6","author":"Neuber","year":"2014","journal-title":"mAbs"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/tbj.12361","article-title":"Milestones in Breast Cancer Treatment","volume":"21","author":"Zurrida","year":"2015","journal-title":"Breast J."},{"key":"ref_56","first-page":"1285","article-title":"EGFR and HER-2 antagonists in breast cancer","volume":"27","author":"Crown","year":"2007","journal-title":"Anticancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10147-006-0575-4","article-title":"Trastuzumab and breast cancer: Developments and current status","volume":"11","author":"Tokunaga","year":"2006","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3816\/CBC.2006.n.040","article-title":"A Phase I Study of Cetuximab\/Paclitaxel in Patients with Advanced-Stage Breast Cancer","volume":"7","author":"Modi","year":"2006","journal-title":"Clin. Breast Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2010.34.5579","article-title":"TBCRC 001: Randomized Phase II Study of Cetuximab in Combination with Carboplatin in Stage IV Triple-Negative Breast Cancer","volume":"30","author":"Carey","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-015-0227-0","article-title":"Bispecific antibodies and their applications","volume":"8","author":"Fan","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1042\/BJ20120433","article-title":"A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells","volume":"445","author":"Yamamoto","year":"2012","journal-title":"Biochem. J."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Scott, C.L., Becker, M.A., Haluska, P., and Samimi, G. (2013). Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Front. Oncol., 3.","DOI":"10.3389\/fonc.2013.00295"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Jiang, A.N., Liu, J.T., Zhao, K., Wu, H., Wang, S., Yan, K., and Yang, W. (2020). Specific Inhibitor of Matrix Metalloproteinase Decreases Tumor Invasiveness After Radiofrequency Ablation in Liver Tumor Animal Model. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.561805"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2174\/156652411795677972","article-title":"Proteolytic Cleavage of Notch: \u201cHIT and RUN\u201d","volume":"11","author":"Vooijs","year":"2011","journal-title":"Curr. Mol. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nprot.2010.13","article-title":"Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine","volume":"5","author":"Vosjan","year":"2010","journal-title":"Nat. Protocol"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1162\/153535003322556877","article-title":"AMIDE: A Free Software Tool for Multimodality Medical Image Analysis","volume":"2","author":"Loening","year":"2003","journal-title":"Mol. Imaging"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Mason, E.O., Goldgur, Y., Robev, D., Freywald, A., Nikolov, D.B., and Himanen, J.P. (2021). Structure of the EphB6 receptor ectodomain. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0247335"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e202403126","DOI":"10.26508\/lsa.202403126","article-title":"Antibodies targeting ADAM17 reverse neurite outgrowth inhibition by myelin-associated inhibitors","volume":"8","author":"Saha","year":"2025","journal-title":"Life Sci. Alliance"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/7\/2936\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:04:00Z","timestamp":1774357440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/7\/2936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":68,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["ijms27072936"],"URL":"https:\/\/doi.org\/10.3390\/ijms27072936","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]}}}